Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Researchers reporting in Aging Cell identified MTR4, an RNA helicase, as a regulator of senescence in the endothelial cells lining blood vessels. MTR4 protein levels fall with age through accelerated ubiquitin-proteasome degradation driven by SYVN1, and restoring MTR4 partially reversed senescent features and reduced inflammatory secretions in human endothelial cells. Because senescent vessel-lining cells release these compounds directly into circulation, the pathway is relevant to vascular aging and age-related cardiovascular disease.
VectorY has expanded its Phase 1/2 PIONEER-ALS trial of VTx-002 from 12 to 36 participants before any efficacy data is available, citing rapid enrollment and site activation. VTx-002 is a vectorized antibody designed to produce sustained antibody expression within the central nervous system against TDP-43, the protein that aggregates abnormally in up to 97% of ALS cases. The open-label, placebo-free design means the larger cohort increases biomarker and functional observations without establishing clinical benefit.
Jupiter Neurosciences has dosed the first patient in RESET, a 30-person Phase 2a trial of JOTROL, a micellar trans-resveratrol formulation, in Parkinson's disease. The study is powered for safety, tolerability and pharmacokinetics — including cerebrospinal fluid levels — with exploratory biomarkers covering energy metabolism and inflammation, not efficacy. The same announcement disclosed that the company has engaged an adviser to evaluate a sale, licensing or other strategic transaction.
Oncologist and researcher Siddhartha Mukherjee outlines how cancer care is shifting toward earlier detection and therapies that exploit the metabolic and immune distinctiveness of malignant cells. He notes that second- and third-line therapies in certain cancers now produce genuine extensions of lifespan rather than marginal delays. For longevity, the practical leverage remains in risk reduction and detecting disease while it is still curable.
In 223,051 men from the UK Biobank, mosaic loss of chromosome Y in blood cells independently predicted incident age-related macular degeneration, with risk escalating beyond a defined threshold of clonal burden. Plasma proteomic shifts appeared up to 15 years before diagnosis, and single-cell data localized the highest Y-loss frequencies to CD16+ monocytes and choroidal macrophages displaying a pro-inflammatory phenotype. A machine learning model built on these protein signatures predicted five-year incident risk with an AUC of 0.734.
Chaperone-mediated autophagy, a selective pathway for degrading damaged intracellular proteins, declines with age and this loss corresponds with a higher burden of senescent cells in tissue. Part of the mechanism involves impaired macrophage surveillance, so senescent cells that would normally be recognized and removed persist, contributing to tissue dysfunction and systemic aging.
A review of patent and development records for 25 widely used gray-market peptides found that most originated within pharmaceutical research programs rather than outside them, with many later discontinued during clinical development. The compounds circulating through compounding pharmacies and online vendors therefore carry documented histories — including the reasons their original sponsors stopped pursuing them — that are rarely referenced in consumer marketing. For anyone considering these agents as longevity interventions, that development record is the most informative available evidence on efficacy and risk.
In aging mice, bone marrow fat cells secrete DPP4 and other factors that activate the cGAS–STING pathway in marrow macrophages, producing chronic inflammatory signaling that suppresses bone formation and lowers NAD⁺ in osteoblast progenitors. Silencing STING specifically in macrophages between 12 and 18 months preserved bone density and architecture, increased new bone deposition, and reduced marrow fat accumulation. The work positions innate immune sensing of displaced DNA as an upstream driver of age-related skeletal decline rather than a bystander.
A post-hoc analysis of Longeveron's 49-person Phase 2a CLEAR MIND trial used free water MRI to assess neuroinflammation in Alzheimer's patients treated with laromestrocel, an allogeneic mesenchymal stem cell product. Reduced inflammatory signal in the left hippocampus and temporal-parietal cortex tracked with less atrophy, better cognitive scores, and lower plasma neurogranin. The findings are exploratory, unreviewed, and hypothesis-generating rather than confirmatory.
Prenuvo has opened an imaging biobank of more than 200,000 whole-body MRI scans to over 50 research institutions, accompanied by four initial studies. The largest reported that roughly 7% of 78,000 self-referred individuals had a clinically significant brain abnormality, including aneurysms, infarcts and meningiomas. The data come from a self-selected population, and whether detection of such findings translates into longer healthy life remains unresolved.
Digbi Health has extended its genomic and gut microbiome platform to menopause care, combining hormone replacement therapy, GLP-1 prescribing, and metabolic and gastrointestinal management under a single clinical team. The rationale rests on member data showing 75% of women aged 40 to 60 already carry an obesity, cardiometabolic or gastrointestinal diagnosis. Separately released IBS outcomes from nearly 16,000 members show symptom improvement at 12 weeks, though the analysis lacks a control group and does not specify the measurement scale.
Monte Rosa's MRT-8102, an oral molecular glue degrader that removes NEK7 to block NLRP3 inflammasome assembly, reduced NEK7 by 80–90% and lowered hsCRP by a median of 85%, IL-6 by 54%, fibrinogen by 28% and lipoprotein(a) by 24% in 108 adults with obesity and elevated cardiovascular risk over four weeks. Downstream plaque-associated damage signals including calprotectin, S100A12 and SAA fell by roughly half, with no increase in infections and adverse event rates comparable to placebo. The data are company-reported, biomarker-based and not yet linked to clinical outcomes.